NCT03395873 is a Phase 1 clinical trial of Avelumab in Acute Myeloid Leukemia, sponsored by Milton S. Hershey Medical Center.

Who is sponsoring NCT03395873?

NCT03395873 is sponsored by Milton S. Hershey Medical Center.

What drugs are being tested in NCT03395873?

Interventions in NCT03395873: Avelumab.

What condition does NCT03395873 study?

NCT03395873 studies Acute Myeloid Leukemia.

Is NCT03395873 still recruiting?

NCT03395873 is currently terminated. Last updated 21 August 2019.

Last reviewed 2019-08-21 · How we verify

NCT03395873

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy

Terminated Phase 1 Last updated 21 August 2019

What this trial tests

Phase 1 trial testing Avelumab in Acute Myeloid Leukemia in 7 participants. Terminated before completion.

Timeline

29 January 2018

Primary endpoint
15 May 2019

15 May 2019

Quick facts

Lead sponsor	Milton S. Hershey Medical Center
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	29 January 2018
Primary completion	15 May 2019
Estimated completion	15 May 2019
Sites	1 location across United States

Drugs / interventions tested

Avelumab (avelumab) — full drug profile →

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →

Sponsor

Milton S. Hershey Medical Center

Who can join

18 and older, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to test the safety of combination treatment with Avelumab and Decitabine in newly diagnosed AML patients who are unfit for intensive induction chemotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity.
Lamble AJ, Lind EF. · · 2018 · cited 95× · PMID 29951373 · DOI 10.3389/fonc.2018.00213
Product review: avelumab, an anti-PD-L1 antibody.
Collins JM, Gulley JL. · · 2019 · cited 62× · PMID 30481100 · DOI 10.1080/21645515.2018.1551671
Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.
Schürch CM. · · 2018 · cited 30× · PMID 29868474 · DOI 10.3389/fonc.2018.00152
Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials.
Xu Y, Li P, Liu Y, Xin D, et al · · 2022 · cited 29× · PMID 35642676 · DOI 10.1002/cac2.12313
Dissecting the Immune Landscape of Acute Myeloid Leukemia.
Davidson-Moncada J, Viboch E, Church SE, Warren SE, et al · · 2018 · cited 24× · PMID 30477280 · DOI 10.3390/biomedicines6040110
Intimate communications within the tumor microenvironment: stromal factors function as an orchestra.
Cheng B, Yu Q, Wang W. · · 2023 · cited 22× · PMID 36600243 · DOI 10.1186/s12929-022-00894-z
A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia.
Zheng H, Mineishi S, Claxton D, Zhu J, et al · · 2021 · cited 20× · PMID 33146922 · DOI 10.1002/ajh.26043
Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML.
Zhao C, Jia B, Wang M, Schell TD, et al · · 2020 · cited 19× · PMID 31573077 · DOI 10.1111/bjh.16228

Verify or expand the search:

Other trials of Avelumab

Trials testing the same drug.

NCT06939036 — Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) · Phase 1, PHASE2 · terminated
NCT05687721 — Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer · Phase 1, PHASE2 · withdrawn
NCT06518564 — Avelumab and M1774 in ARID1A-mutated Endometrial Cancer · Phase 2 · recruiting
NCT06424717 — Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L · Phase 2 · withdrawn
NCT06302426 — Trial of INI-4001 in Patients With Advanced Solid Tumours · Phase 1 · recruiting

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other Milton S. Hershey Medical Center trials

Trials by the same sponsor.

NCT05180552 — The HEALiX: Comparing the Efficacy of the HEALiX Device With Wrist Restraints in a Critical Care Setting · NA · withdrawn
NCT07461844 — Transdiagnostic Sleep and Circadian Treatment for Autistic Adults · NA · not yet recruiting
NCT06253858 — Ultrasound (US) Guided External Ventricular Catheter Placement · NA · not yet recruiting
NCT07225699 — IN PATIENTS WITH CORNEAL ABRASIONS TREATED WITH COLLAGEN CORNEAL SHIELDS IN THE EMERGENCY DEPARTMENT SETTING · NA · not yet recruiting
NCT07461168 — Penn State Emergency Medicine CarES: Care-partner Evaluation and Sourcing in the Emergency Department · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03395873 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Milton S. Hershey Medical Center
Last refreshed: 21 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03395873.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing